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Simple Summary: Pancreatic ductal adenocarcinoma (PDAC) has a poor 5-year survival rate and is
the 7th leading cause of cancer-related deaths in the world. The high mortality for this disease is
partly due to late presentation rendering therapeutics ineffective. Since a majority of patients are
diagnosed at advanced stages due to the lack of specific symptoms, and the prognosis is linked to
the stage of detection, there is a need for robust early detection methods for PDAC. Here, we review
the potential use of circulating tumour DNA (ctDNA) as a non-invasive biomarker in the early
detection of pancreatic cancer. In brief ctDNA levels in blood correlate with disease progression but
its widespread application for early PDAC detection requires further investigation and potentially,
a combination of ctDNA sequence and methylome analysis with other, protein-based biomarkers.
Abstract: Pancreatic cancer is a lethal disease, with mortality rates negatively associated with the stage
at which the disease is detected. Early detection is therefore critical to improving survival outcomes.
A recent focus of research for early detection is the use of circulating cell-free tumour DNA (ctDNA).
The detection of ctDNA offers potential as a relatively non-invasive method of diagnosing pancreatic
cancer by using genetic sequencing technology to detect tumour-specific mutational signatures in
blood samples before symptoms manifest. These technologies are limited by a number of factors that
lower sensitivity and specificity, including low levels of detectable ctDNA in early stage disease and
contamination with non-cancer circulating cell-free DNA. However, genetic and epigenetic analysis
of ctDNA in combination with other standard diagnostic tests may improve early detection rates.
In this review, we evaluate the genetic and epigenetic methods under investigation in diagnosing
pancreatic cancer and provide a perspective for future developments.
Keywords: circulating cell-free tumour DNA; pancreatic cancer; pancreatic ductal adenocarcinoma
1. Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the 14th most prevalent cancer and the seventh most
common cause of cancer-related death worldwide [1]. Its incidence is expected to double by 2030,
becoming the second-leading cause of cancer-related death in the United States [2,3]. Pancreatic ductal
adenocarcinoma also has the lowest five-year survival rate of any malignancy, which is around
5–10% [4,5]. This is attributed to the disease frequently presenting and/or being detected in an advanced
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stage, in which a cure is highly unlikely [6]. Indeed, a potential cure for PDAC involves surgical
resection with adjuvant chemotherapy [7]. Alternatively, borderline resectable and locally advanced
PDAC cases may benefit from neoadjuvant therapy, which can be safer than surgery. A number of
studies have compared the two approaches [8–13], but the broad clinical utility of neoadjuvant therapy
still requires further investigation in a phase 3 clinical trial setting [14]. Altogether, approximately
85% of patients diagnosed with PDAC are not suitable for potentially curative therapy due to locally
advanced or metastatic spread. Early detection of PDAC is thus critical to allow access to surgery and
therefore, for the improvement in survival outcomes for patients. One area of current research is using
liquid biopsies to detect the disease at an early stage.
The development of next-generation DNA sequencing methods, together with technical advances
in molecular biology, has sparked interest in liquid biopsy as a tool for the early detection of
cancer [15]. Currently, the only blood-based marker used in the diagnosis of pancreatic cancer is serum
CA19.9 [16]; however, its relatively low sensitivity (79%) and specificity (82%) limits its validity as a
stand-alone test [17,18]. Newly uncovered circulating biomarkers raise hopes for more sensitive and
specific diagnostic tests that can analyse a myriad of body fluids e.g., saliva, blood or urine [19–21].
Such methods include the detection of exosomes, DNA, RNA or circulating tumour cells (CTCs)
(Figure 1). The numbers of detectable CTCs are often low in many tumour types, particularly in early
stage disease, and there are no validated biomarkers for cell selection, making this approach somewhat
limited [22]. In contrast, circulating nucleic acids are more prevalent in early stage disease, offering a
potential biological marker for detection. In this review, we discuss the application of circulating
tumour DNA (ctDNA) in the early detection of pancreatic cancer.
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2. Liquid Biopsies for ctDNA
A liquid biopsy is a non-invasive investigation that holds great promise in detecting early stage
cancer. It involves sampling blood and/or other body fluids for the presence of ctDNA or CTCs.
Initial research has focused on advanced cancers, where ctDNA levels are highest and therefore
isolation and sequencing of tumour-specific nucleic acids are more feasible [23,24]. Indeed, in advanced
stage pancreatic cancer, the presence of ctDNA in the blood has been associated with both relapse and
residual disease following surgery [25,26], and could be used to tailor therapeutic approaches [27].
Liquid biopsies are more accessible than tumour biopsies, and can provide a new diagnostic tool,
particularly in tumour types where invasive biopsies are comparatively more unsafe and difficult.
In addition, while single-site tumour biopsies may not reflect tumour heterogeneity, particularly
in metastatic disease, ctDNA analysis offers the potential to provide a method to detect inter- and
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intra-tumour heterogeneity across metastatic sites [28]. Therefore, ctDNA analysis offers the potential
to detect early stage PDAC and reduce the number of potentially harmful procedures, as well as
limiting costly and unnecessary therapies that may be associated with toxicity [29].
Circulating cell-free DNA in blood was first described by Mandel and Metais in 1948 [30].
Subsequent investigations led to the observation in 1977 by Leon et al. [31] that circulating cell-free
DNA (cfDNA) levels are increased in cancer. Further studies have since indicated that cfDNA levels
are also elevated in other pathophysiological processes, such as following physical trauma [32],
cerebral infarction [33], physical exercise [34] and solid organ transplantation [35]. Another major
breakthrough came from the discovery of the presence of foetal Y-chromosomal cfDNA in maternal
blood [36], which led to the development of non-invasive prenatal testing [37]; a screening method
now used to detect congenital chromosomal abnormalities [38–40]. In the context of cancer medicine,
cfDNA studies have shown that the fraction of the cfDNA produced directly from cancer cells
(i.e., ctDNA) can also be detected, but has a shorter half-life than non-cancerous cfDNA [41] and
therefore requires almost immediate sample processing.
Circulating cell-free DNA is fragmented, typically double-stranded and approximately
150–350 base pairs in length [42]. It can be released from a variety of healthy cells, but the majority
originates from haematopoietic cells [43,44]. In patients diagnosed with cancer, cfDNA is also released
from cancer cells, though the mechanism of ctDNA release remains unclear—either active secretion
and/or release in cell death, supported by studies showing that ctDNA levels increase rapidly after
treatment is administered in a range of cancers [45–47]. The mechanism of DNA release might
affect cancer detection, as actively secreted ctDNA may be biased in certain chemotherapy-sensitive
metastatic sites. ctDNA constitutes between approximately 0.1% and >90% of all cfDNA depending on
a number of factors, in particular cancer stage [24,48]. Moreover, Bettegowda et al. showed that early
stage cancers have a lower percentage of ctDNA then late stage malignancies [24]. For pancreatic cancer,
ctDNA was detected in 48% of patients with localised tumours, but in more than 80% of advanced
cancers. This shows a potential limitation of ctDNA as an early detection tool for pancreatic cancer.
3. Detection of ctDNA
An important property of ctDNA related to early cancer detection is its low stability;
different studies estimate ctDNA half-life to be between 16 and 150 min [48–50], thus necessitating
longitudinal analysis of tumour responses to therapy and/or disease progression. This short half-life
also brings a technical challenge: the instability of cfDNA combined with the propensity for blood
cells to lyse once outside the body, resulting in contamination, necessitates cfDNA separation by
centrifugation within no more than 4 h of sample collection in standard phlebotomy tubes [15,51,52],
which creates logistic burden and does not allow for central processing in specialised centres, therefore
limiting widespread clinical implementation. In an attempt to address this issue, recent developments
allow for the ability to fix and stabilise cfDNA for 7–14 days at room temperature [53]. Specifically,
Cell-Free DNA BCT® (Streck, La Vista, NV, USA) tubes are estimated to preserve cfDNA in blood for
7 days due to an improved vacuum and moisture retention system [54–56] and have been used in a
number of recent diagnostic studies of different tumour types [57,58].
Another significant challenge in the diagnostic utility of ctDNA is its low concentration in plasma,
complicating detection and analysis. There is approximately 10–15 ng of cfDNA per millilitre and ctDNA
constitutes a small fraction of cfDNA in most early stage of cancers [48]. These factors highlight the need
for ultrasensitive detection techniques. In clinical trials, current sequencing methods involve targeted
or genome-wide approaches to genetic sequencing. The former is more prevalent and only detects
hotspot mutations in specific genes. This technology could be applicable to somatic KRAS mutations
ubiquitously found in PDAC. Conversely, genome-wide sequencing assays are an unrestricted method
that is more expensive and technically challenging, but identifies many more mutations across the
genome as well as structural variants and mutational signatures. Currently, the most sensitive methods
are polymerase chain reaction (PCR)–based approaches, including single-molecule PCR BEAMing [59],
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TAm-Seq [60], digital PCR [61] and droplet digital PCR [62]. Next-generation sequencing techniques are
also widely used, with the biggest limiting factor being the low fidelity of DNA polymerase [60,63,64].
However, the incorporation of deep sequencing, molecular barcoding and digital error suppression
can increase sensitivity and specificity of the approach [65,66].
4. ctDNA in Pancreatic Cancer
Initial insights into the utility of ctDNA in the diagnosis of pancreatic cancer were elucidated by
Shapiro et al. [67], who showed that ctDNA can be found in patients diagnosed with pancreatic cancer,
but is absent in healthy individuals. Almost 10 years after these initial findings, Sorenson et al. [68]
were able to detect somatic KRAS mutations in the plasma of patients diagnosed with pancreatic
cancer. These mutations matched those found in the tumour, sparking interest in ctDNA as an early
detection marker for pancreatic cancer. Indeed, KRAS is a candidate gene for early detection because it
is considered a clonal oncogenic driver of pancreatic cancer and is present in ~95% of cases [69,70].
A description of the most relevant studies of ctDNA application in PDAC detection and monitoring is
provided in Table 1.
Cancers 2020, 12, 3704 5 of 16
Table 1. Clinical studies investigating ctDNA in pancreatic cancer.









KRAS mutation found in blood of
patients with PC, the mutations were
identical with those in tumour biopsy
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KRAS2 mutation detected in 47%
patients with PC, and in 13% of
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KRAS2 + CA19.9 increased sensitivity
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KRAS mutation found in 70.7% of
patients with PC but not in
21 controls. Combined with CA19–9,
proportion increased to 90.2%
58 + 21 ctrl 70.7%/90.2%with CA19–9 N/A
KRAS/KRAS +
CA19–9




ctDNA exceeding 62 ng/mL linked to
lower OS and metastasis N/A N/A N/A N/A
Sausen et al., 2015
[25] Stage II of PC NGS, ddPCR
ctDNA detected in 43% of patients,
ctDNA linked to an adverse
prognosis and predicted relapse
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71% N/A KRAS mutations
Berger et al., 2016
[74] Metastatic PC ddPCR
KRAS mutation in 41.7% of patients,
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Table 1. Cont.
Author Cancer Type Detection Method Interpretation Number ofPatients (n) Sensitivity Specificity
Diagnostic
Targets
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Cheng et al., 2017
[79] Metastatic PC ddPCR, NGS
72.3% of PC patients presented with
ctDNA-detected KRAS mutation
10: exome seq,
188 ddPCR, 76.9% N/A 60 genes screened




ctDNA found in 48% of patients with
PC, the presence of ctDNA was a
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135, 31 resectable 48% N/A N/A
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The presence of ctDNA or elevated
cfDNA linked to poor prognosis
1243 from 18
articles N/A N/A N/A







ctDNA showed no correlation with
outcomes, as opposed to exosome
levels. However, detection of ctDNA














CA19–9, THBS2 and cfDNA levels in
combination were a better PC
biomarker (c-statistics 0.90) than any
of those separately
52 90% N/A thrombospondin-2(THBS2), CA19–9







ctDNA fragmentation pattern may
affect the detection of early PC;
cancer-specific mutations found in







* Early PDAC detection study. CA19–9, carbohydrate antigen 19–9; cfDNA, cell-free DNA; ctDNA, circulating tumour DNA; ctrl, control; ddPCR, digital droplet PCR; IPMN,
intraductal papillary mucinous neoplasms; NGS, new-generation sequencing; OS, overall survival; PC, pancreatic cancer; PCR, polymerase chain reaction; PCR-RFLP, PCR Restriction
Fragment Length Polymorphism; PDAC, pancreatic ductal adenocarcinoma; PFS, progression-free survival; SCA, serous cystadenoma.
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5. The Use of ctDNA to Detect Early Stage Pancreatic Cancer
Despite the promising results emerging from ctDNA use, the clinical applicability of liquid biopsy
remains debatable across tumour types. A number of studies have shown low sensitivity and specificity
of ctDNA application, particularly in breast [85] and lung [86] early stage cancers. Similarly, in a
large case–control study, Calvez-Kelm et al. [76] reported that ctDNA is a less accurate method to
detect early stage PDAC than CA19–9, and a combination of the two tests did not increase sensitivity.
This finding was supported by a more recent study by Fiala et al. [87], which showed that the current
sequencing technology was unable to detect ctDNA of pancreatic cancer less than 10 mm in diameter
with detection efficiency increasing with cancer progression.
As a result, ctDNA analysis for early detection is currently unable to be used as a stand-alone
method to detect early stage cancer [24]. Therefore, various approaches of combining ctDNA with
other molecular biomarkers are being evaluated. Several studies have reported the applicability of such
approaches in PDAC. Indeed, CA19–9 was shown to be a less sensitive marker than when combined
with TIMP-1 protein testing [88]. In another study, Capello et al. showed that the sensitivity of PDAC
detection is even higher when the two factors are combined with LRG-1 protein testing [89]. In an
attempt to integrate protein biomarkers and ctDNA in PDAC detection, Cohen et al. [78] presented
a study incorporating the data from KRAS ctDNA sequencing and four additional protein markers
(CA19–9, CEA, HGF and OPN) and reported an increased specificity and sensitivity in early stage
pancreatic cancer detection.
A similar method was exploited by Cohen et al. [80] in 2018. This group used CancerSEEK
technology, based on ultra-deep PCR-based sequencing, to analyse 1933 distinct genomic loci combined
with eight protein biomarkers. Based on data from liquid biopsies taken from 1005 patients with early
stage, resectable cancer and 812 healthy individuals, the sensitivity rate of detection varied from 43%
in stage I, 72% in stage II to 78% in stage III with specificity exceeding 99% (7 out of 812 controls were
identified as cancer-positive). The sensitivity also varied based on tumour type e.g., 33% in breast
cancer, 98% in ovarian cancer and 72% in pancreatic cancer. However, the accuracy of the approach
has been questioned. In particular, Young et al. [90] criticised the use of case–control data where
subject selection and the choice of a robust control are challenging. Specifically, no advanced stage
cancers were included, and the healthy controls were likely to be biased and not represent the potential
screening population (e.g., individuals with gastrointestinal tract symptoms or those characterised
by genetic predispositions). In addition, the cases analysed included eight different cancer types of
various stages, and it may therefore not be possible to draw robust conclusions about the utility of this
approach in a single tumour type. For these reasons, the sensitivity and specificity reported could be
biased and an additional study is required to validate the method.
One challenge related to ctDNA biology is a lack of consistency in the study design. As investigated
tumour stages vary between studies, which include both case–control and cohort studies, a robust
comparison of different methods is challenging. Moreover, PDAC should be confirmed using
established techniques (e.g., histology), with a follow-up period for the detection of false-negative
early stage cancers. In addition, controls should consist of individuals in high-risk groups, likely to
be frequently screened, as well as healthy volunteers. If possible, calculations of sensitivity and
specificity should be applied to each tumour type and stage separately to enable reliable comparison
between studies.
Efficient, early diagnosis of PDAC also requires the identification of a screening population at
risk of developing PDAC. There is a number of risk factors associated with PDAC, with the most
relevant being new-onset diabetes mellitus [91], chronic pancreatitis [92] or genetic predisposition [93].
Ben et al. showed that, while long-lasting diabetes mellitus increases the risk of developing PDAC by
1.5-fold, recent detection (within 1–3 years from the disease onset) increases this ratio to 5–8-fold [94].
Similarly, the risk of developing PDAC increases eightfold over the five-year period following chronic
pancreatitis diagnosis [92]. Finally, genetic predispositions are estimated to contribute to 5–10% of all
PDAC cases [93], with mutations in the six most significant genes being reported in 5.5% of patients [95].
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Altogether, the currently available data point at certain risk factors, which should determine the
screening population for PDAC using ctDNA-based liquid biopsy.
6. Methylation Analysis in Cancer Diagnosis Based on Liquid Biopsy
Genome-wide epigenetic changes are common in cancer. Somatic methylations can be
cancer-driving events and may precede genetic mutations during carcinogenesis [96–98]. As a result,
epigenetics has attracted considerable research attention over the recent years. Introducing this
property into ctDNA testing brings hope to increase the clinical utility of liquid biopsies [29].
Methylations of CpG islands provide a method to regulate gene expression by modulating
transcription. The differences in methylation occupancy underlie many cancer types, with tumour
suppressor genes being most frequently affected [99]. Certain methylations are tumour specific and
therefore could be used to detect cancer as well as its tissue of origin based on ctDNA analysis.
For example, HOXA9 is methylated in 95% of high-grade ovarian serous carcinomas and together with
EN1 methylation levels can be used to distinguish between benign and malignant ovarian tumours
with up to 98.8% sensitivity and 91.7% specificity [100].
Methylation assays for cfDNA have also been shown to be useful for PDAC detection and
progression-tracking. Henriksen et al. [101] demonstrated that cancer-specific promoter methylation
can be a marker for early PDAC detection. Moreover, Ligget et al. [102] showed that methylation
analysis of 17 gene promoters in ctDNA was able to distinguish between patients diagnosed with
chronic pancreatitis and PDAC with a sensitivity of 91.2% and specificity of 90.8%. More recently,
Eissa et al. [103] identified the methylation of ADAMTS1 and BNC1 in ctDNA as a diagnostic biomarker
in PDAC. Indeed, for localised PDAC, the sensitivity of this two-gene panel ctDNA analysis was 94.8%,
and the specificity was 91.6%. These findings show promise in the early detection of PDAC and may
enable differentiation from chronic pancreatitis.
A larger and more complex study was performed by Liu et al. [58], who investigated ctDNA
application in early cancer detection in 15,254 subjects with or without over 50 types of cancer. The most
relevant methylation regions were identified using whole-genome methylation assays followed by a
wide-range analysis of the cancer detection properties. Subsequently, a targeted methylation assay
was tested on a separate group of patients of all cancer stages. Specifically, stage I PDAC was detected
with 63% sensitivity and 99% specificity, rising to 83% and 99%, respectively, in stage II. Taken together,
these data provide further evidence that targeted ctDNA methylation analysis could be used in the
early detection of PDAC.
Despite the improvements in sequencing technology, the low ctDNA concentration in patients
with early stage disease is still one of the most significant challenges to the introduction of methylation
analysis of ctDNA at the initial stage of cancer. So far, various attempts to unravel the methylome
of ctDNA for cancer detection or monitoring have been done with whole-genome bisulphite
sequencing [44,104]. However, this method is limited by input DNA degradation during bisulfide
conversion [105], particularly in early cancer detection when a large enough blood sample would be
required (with standard intake of up to 80 mL of whole blood) and ctDNA can constitute less than
0.1% of the cfDNA fraction [28]. Moreover, the methylome reflects both normal tissue and cancer
heterogeneity and its analysis is thus complex, requiring a substantial amount of comparative data.
Therefore, new methods are being developed to increase the efficiency of this technique. In 2018,
Shen et al. [106] demonstrated a novel approach based on targeted amplification of cancer-specific
methylation regions using Enterobacter phage lambda DNA to increase the initial DNA amount to at
least 100 ng, increasing detection efficiency. Although this method demonstrates improved ctDNA
methylome detection in a cost-effective manner, there is little knowledge of the cancer-specific DNA
methylome, so a genome-wide methylation analysis appears to be more suitable.
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7. Technical Advances Facilitate the Detection and Analysis of ctDNA and Also Unravel
Its Properties
The discovery of ctDNA being typically shorter than cfDNA could be used for ctDNA isolation
by size. The methylation pattern could also be exploited to detect cancer, instead of screening for
specific methylations. Cancer progression is linked to genome-wide methylation loss, along with an
accumulation of methyl groups in the regulatory regions of certain genes [107]. This property has
been exploited by Sina et al. [108] who developed a promising method for cancer detection based
on Methylscape analysis, leading to the increased aggregation of ctDNA on gold beads. Despite the
low specificity observed and small sample size, the study presented a novel approach to ctDNA
analysis. A description of the most relevant methylation studies of ctDNA application in the early
PDAC detection is provided in Table 2.
Table 2. Selected methylation studies of ctDNA in pancreatic cancer.












































































ctDNA, circulating tumour DNA; PC, pancreatic cancer; PDAC, pancreatic ductal adenocarcinoma.
8. Future Directions
Increasing understanding of cancer pathology and the introduction of early detection as well as
targeted and immuno-therapies have revolutionised cancer care. Despite these advances, cancer is
still the third leading cause of death in the world. Improving the detection of early stage disease
is a promising strategy to advance survival outcomes [109]. ctDNA is a promising diagnostic
biomarker, but does not yet represent a validated method for cancer detection. Newer approaches
incorporate additional properties of ctDNA beyond sequencing, such as the length of fragments or
methylation signatures, combined with cancer-associated protein biomarkers. This integrative approach
is continuously revised and improved following technological advancement. Hence, ctDNA analysis
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has the potential to be introduced as a screening tool to detect early stage cancer, particularly in
high-risk groups.
9. Conclusions
Circulating cell-free DNA analysis has a potential role in a number of clinical scenarios, including
early cancer detection. However, studies on the applicability of ctDNA testing in clinical practice have
had mixed outcomes and few ctDNA assays have so far demonstrated promise in the diagnosis of
pancreatic cancer. The incorporation of additional markers and methylome analysis has been shown to
improve the specificity and sensitivity of ctDNA analysis. Further evaluation is required before the
introduction of ctDNA into pancreatic cancer detection and monitoring in clinics.
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